5
Oct 2026
ASAC trial reveals aspirin fails to improve metastatic colorectal cancer survival
Colorectal cancer is one of the most common cancers worldwide, and up to half of patients develop liver metastases during the course of their disease.

Increasing and changing demands concerning the health of populations and limited resources require our health care organizations and systems to rethink their sustainability. To achieve objectives, such as improved healthcare quality, health outcomes, efficiency and staff satisfaction, we support our clients in making evidence-based decisions. With tailor-made research projects, we provide insights into what works, for whom, at what cost, and under what circumstances. Based on your challenge, we can support you by:
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
5
Oct 2026
Colorectal cancer is one of the most common cancers worldwide, and up to half of patients develop liver metastases during the course of their disease.
5
Oct 2026
From temporary changes in kidney filtration to the competing nutritional needs of older adults and children, researchers examine when high protein intake may shift from adaptation to concern.
5
Oct 2026
Chronic night shifts alter circadian gene activity in female healthcare workers.
5
Oct 2026
In a population-based cohort of 8,398 adults in Leipzig, Germany, poorer nutritional status measured using several laboratory-based scores was associated with a higher risk of all-cause mortality over a median follow-up of about 7.5 years.